Modified C-ring (except Methyl In 13-position) (e.g., Double Bond Containing, Substituted, Etc.) Patents (Class 514/179)
-
Publication number: 20140107089Abstract: Disclosed are compounds having the general formula: wherein R1-R4 and X are as defined herein, pharmaceutical compositions including such compounds, and a method of treating a patient involving antagonizing the endogenous progesterone, such as in inducing menses and treating endometriosis, dysmenorrhea, endocrine hormone-dependent tumors, meningiomas, uterine leiomyomas, or uterine fibroids, inhibiting uterine endometrial proliferation, inducing cervical ripening, inducing labor, and in contraception.Type: ApplicationFiled: September 10, 2013Publication date: April 17, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Hyun K. Kim, Richard P. Blye, Pemmaraju N. Rao, James W. Cessac, Carmie K. Acosta, Anne Marie Simmons
-
Publication number: 20140100208Abstract: Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.Type: ApplicationFiled: October 7, 2013Publication date: April 10, 2014Applicant: PregLem S.A.Inventors: Bartholomeus C.J.M. Fauser, Ernest Loumaye
-
Publication number: 20140100207Abstract: A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells.Type: ApplicationFiled: October 9, 2013Publication date: April 10, 2014Applicant: INTELLECTUAL WELLNESS, LLCInventor: Eric Marchewitz
-
Publication number: 20140088058Abstract: The present invention relates to a new pharmaceutical product containing an antiprogestin molecule, such as mifepristone (RU486), administered by the nasal route and to be used to modulate the timing of the spontaneous LH surge as part of follicular stimulation cycles intended for Assisted Reproductive Technology (ART). In particular, it details the route of administration and the dosages that ensure effective delay of the LH surge without incurring in the antifolliculogenetic effects of the antiprogestinic. It also details the overall treatment method as resulting from the use of the new drug product.Type: ApplicationFiled: November 25, 2013Publication date: March 27, 2014Applicant: PARTHENOGEN SAGLInventor: Dattilo Maurizio
-
Patent number: 8679470Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.Type: GrantFiled: November 28, 2008Date of Patent: March 25, 2014Assignee: LuroMed LLCInventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
-
Patent number: 8680326Abstract: The hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3,5-Dihydroxy-3-(2-hydroxy-acetyl)-3a,6-dimethyl-7-oxo-dodecahydro-cyclo-penta[alpha]naphthalen-6-yl]-propionic acid, designated as Deina®, is used in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin.Type: GrantFiled: November 26, 2010Date of Patent: March 25, 2014Inventor: Giovanni Barco
-
Patent number: 8673887Abstract: The present invention relates to compounds and methods which may be useful for the treatment of inflammatory bowel disease, Crohn's disease and colitis.Type: GrantFiled: November 15, 2012Date of Patent: March 18, 2014Assignee: Reveragen Biopharma, IncInventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
-
Publication number: 20140065214Abstract: The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.Type: ApplicationFiled: April 10, 2013Publication date: March 6, 2014Applicant: Horizon Pharma AGInventor: Horizon Pharma AG
-
Publication number: 20140066417Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.Type: ApplicationFiled: November 1, 2013Publication date: March 6, 2014Applicant: DRAWBRIDGE PHARMACEUTICALS PTY LTDInventors: JULIET MARGUERITE GOODCHILD, COLIN STANLEY GOODCHILD, BENJAMIN JAMES BOYD
-
Publication number: 20140065226Abstract: A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having a side chain-linked amino acid. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nano-particle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.Type: ApplicationFiled: March 5, 2012Publication date: March 6, 2014Inventors: Eric Brey, Jennifer J. Kang-Mieler, Victor Perez-Luna, Bin Jiang, Pawel Drapala, Rolf Schäfer, Hans Hitz
-
Publication number: 20140056916Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: ApplicationFiled: October 18, 2013Publication date: February 27, 2014Applicants: THE HOSPITAL FOR SICK CHILDREN, HUMAN MATRIX SCIENCES, LLCInventors: Aleksander HINEK, Thomas F. MITTS
-
Patent number: 8653056Abstract: The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is —OC—R—COOH, substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is —OC—R—COOH, quarternary ammonium substituents of general formula Xb bound to the carboxy group of the terpenoid, wherein Xb is —(CH2)nN+R3Y—, quarternary ammonium substituents of general formula Xc bound to the carboxy group of the terpenoid, wherein Xc je —(CH2)nR+Y—, substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents —R—COOH, glycosylic substituents Xe bound by alpha or beta glycosidic bond to the hydroxy group or to the carboxy group of the teType: GrantFiled: September 25, 2007Date of Patent: February 18, 2014Assignees: Univerzita Karlova V Praze, Prirodovedecka Fakulta, Univerzita Palackeho V Olomouci, I.Q.A., A.S.Inventors: Jan Sarek, Marian Hajduch, Michal Svoboda, Katerina Novakova, Pavla Spacilova, Tomas Kubelka, David Biedermann
-
Publication number: 20140044706Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.Type: ApplicationFiled: June 7, 2013Publication date: February 13, 2014Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
-
Publication number: 20140030233Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.Type: ApplicationFiled: March 15, 2013Publication date: January 30, 2014Applicant: POP TEST CORTISOL LLCInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Publication number: 20140031326Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.Type: ApplicationFiled: November 17, 2011Publication date: January 30, 2014Applicant: WHITE MOUNTAIN PHARMA. INC.Inventors: Hillary D. White, Robert Gyurik
-
Publication number: 20140031327Abstract: The invention provides inhibitors of ?-crystallin aggregation and methods of using ?-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (Tm) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.Type: ApplicationFiled: July 17, 2013Publication date: January 30, 2014Applicant: REGENTS OF THE UNIVERSITY OF MICHIGANInventor: Jason E. Gestwicki
-
Publication number: 20140024627Abstract: The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease.Type: ApplicationFiled: January 3, 2012Publication date: January 23, 2014Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTESInventors: Francine Behar-Cohen, Elodie Bousquet
-
Patent number: 8633179Abstract: The present invention relates to methods and compositions for preventing and/or treating various conditions in a patient, including for example, T-cell lymphoblastic leukemia and lymphoma as well as neurodegenerative diseases, such as for example, Alzheimer's disease. In one preferred embodiment of the invention, such methods include providing a patient with an effective amount of a combination of a NOTCH-1 inhibitor and glucocorticoid. The present invention further encompasses methods for increasing the efficacy of, and mitigating resistance to, glucocorticoids in the treatment of T-cell lymphoblastic leukemia and lymphoma, which generally include providing a patient with an effective amount of one or more NOTCH-1 inhibitors.Type: GrantFiled: March 13, 2008Date of Patent: January 21, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Adolfo A. Ferrando, Pedro J. Real
-
Publication number: 20140017175Abstract: Novel pentablock polymers comprising PGA-PCL-PEG-PCL-PGA or PEG-PCL-PLA-PCL-PEG, wherein PEG is polyethylene glycol, PCL is poly(?-caprolactone), PGA is poly(glycolic acid), and PLA is poly(lactic acid).Type: ApplicationFiled: September 17, 2013Publication date: January 16, 2014Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: ASHIM K. MITRA, GYAN PRAKASH MISHRA
-
Publication number: 20140011790Abstract: This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of CD14+/DR? cells (e.g., CD14+/DR? monocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that change the ratio of CD14+/HLA-DR? cells to CD14+/HLA-DR+ cells as well as methods and materials for (a) identifying a mammal as being likely to experience an elevated level of CD14+/DR? cells (e.g., CD14+/DR? monocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that reduce the degree to which the mammal develops CD14+/DR? cells are provided.Type: ApplicationFiled: April 5, 2012Publication date: January 9, 2014Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Allan B. Dietz, Peggy A. Bulur
-
Publication number: 20140010823Abstract: A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.Type: ApplicationFiled: August 29, 2013Publication date: January 9, 2014Applicant: Allergan, Inc.Inventors: Michael R. Robinson, Joan-En Chang-Lin, Devin F. Welty, Patrick M. Hughes, Scott M. Whitcup
-
Publication number: 20140011785Abstract: The present invention relates to antiandrogenic compounds which may be administered for the treatment of androgen excess in the skin and by way of consequence, the treatment of acne, baldness or hirsuitism in subject or patient.Type: ApplicationFiled: September 6, 2013Publication date: January 9, 2014Applicant: Yale UniversityInventor: Richard Hochberg
-
Publication number: 20140005157Abstract: A method and intravaginal drug delivery device for reducing size of a uterine fibroid in a female in need thereof are provided. The method includes administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to uterine fibroid, wherein said amount is able to significantly reduce the size of the uterine fibroid, wherein the active agent is any one of selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.Type: ApplicationFiled: September 4, 2013Publication date: January 2, 2014Applicant: ARSTAT Inc.Inventor: Arkady RUBIN
-
Publication number: 20140005158Abstract: The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: Corcept Therapeutics, Inc.Inventor: Joseph K. Belanoff
-
Publication number: 20140004171Abstract: A method and intravaginal drug delivery device for reducing size of endometrial implants in a female in need thereof are provided. The method includes administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to the endometrial implants, wherein said amount is able to significantly reduce the size of endometrial implants, wherein the active agent is any one of selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.Type: ApplicationFiled: September 4, 2013Publication date: January 2, 2014Applicant: ARSTAT Inc.Inventor: Arkady RUBIN
-
Publication number: 20130331366Abstract: The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible.Type: ApplicationFiled: August 12, 2013Publication date: December 12, 2013Applicant: DANCO LABORATORIES LLCInventor: Richard Hausknecht
-
Publication number: 20130331365Abstract: The present invention provides methods of preventing or delaying the development of cancer (e.g., breast cancer) in BRCA1 mutation positive patients by beginning progesterone receptor antagonist treatment at an early age (e.g., by age 35, 30, or 25). In certain embodiment, such early treatment is long-term treatment, which may substitute or delay a preventative ovariectomy, single or double mastectomy (e.g., in patients wishing to delay or avoid a mastectomy, or patients that cannot afford a mastectomy).Type: ApplicationFiled: August 19, 2013Publication date: December 12, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Eva Y.H.P. Lee
-
Publication number: 20130323179Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.Type: ApplicationFiled: May 3, 2013Publication date: December 5, 2013Applicant: Johns Hopkins University, TheInventors: Alexey Popov, Elizabeth M. Enlow, James Bourassa, Colin R. Gardner, Hongming Chen, Laura M. Ensign, Samuel K. Lai, Tao Yu, Justin Hanes, Ming Yang
-
SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS
Publication number: 20130324509Abstract: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury.Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicant: InVivo Therapeutics CorporationInventors: Christopher D. Pritchard, Robert S. Langer, Francis M. Reynolds, Eric J. Woodard -
Publication number: 20130323301Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.Type: ApplicationFiled: October 31, 2011Publication date: December 5, 2013Applicant: TOCAGEN INC.Inventors: Harry E. Gruber, Douglas J. Jolly, Derek G. Ostertag, Ryan S. Burnett, Amy H. Lin, Tiffany Huang, Joan M. Robbins
-
Publication number: 20130324500Abstract: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury.Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicant: InVivo Therapeutics CorporationInventors: Christopher D. Pritchard, Robert S. Langer, Francis M. Reynolds, Eric J. Woodard
-
Publication number: 20130316992Abstract: The present invention provides gene expression profiles indicative of whether a patient afflicted with PR driven malignancies is likely to be responsive to treatment with a therapeutic compound that is an anti-progestin. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. Also, provided are methods of using gene expression profiles and assays for identifying the presence of a gene expression profile in a patient.Type: ApplicationFiled: March 15, 2013Publication date: November 28, 2013Inventors: Carol Lange, Todd Knutson, Jason Basil Nikas
-
Publication number: 20130316006Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: ApplicationFiled: May 3, 2013Publication date: November 28, 2013Applicant: Kala Pharmaceuticals, Inc.Inventor: Kala Pharmaceuticals, Inc.
-
Publication number: 20130315981Abstract: The present invention is a method of increasing lipolysis in an adipose tissue of a mammal comprising delivering to macrophages at the adipose tissue of the mammal an effective amount of an agent which reduces the concentration of macrophages at the adipose tissue of the mammal, thereby increasing lipolysis in the adipose tissue of the mammal.Type: ApplicationFiled: June 22, 2011Publication date: November 28, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: Anthony W. Ferrante, JR., Aliki Kosteli
-
Publication number: 20130316001Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: ApplicationFiled: May 3, 2013Publication date: November 28, 2013Applicant: Kala Pharmaceuticals, Inc.Inventor: Kala Pharmaceuticals, Inc.
-
Publication number: 20130303473Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.Type: ApplicationFiled: November 10, 2011Publication date: November 14, 2013Applicant: NOVALIQ GmbHInventor: Clive G. Wilson
-
Publication number: 20130303985Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.Type: ApplicationFiled: April 5, 2013Publication date: November 14, 2013Inventors: Paul K. Wotton, Kaushik J. Dave, John W. Hayes, Peter L. Sadowski, Hermanus L. Jooste, Jonathan Jaffe
-
Patent number: 8574622Abstract: This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.Type: GrantFiled: July 30, 2011Date of Patent: November 5, 2013Assignee: M & P Patent AktiengesellschaftInventor: Claudia Mattern
-
Publication number: 20130289008Abstract: The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associated with endometriosis. The compositions may be administered to females with endometriosis as well as to females undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. In certain embodiments, the invention provides a method for suppressing endometrial proliferation.Type: ApplicationFiled: April 2, 2013Publication date: October 31, 2013Applicant: REPROS THERAPEUTICS INC.Inventor: Joseph S. Podolski
-
Patent number: 8569276Abstract: The present invention relates, inter alia, to compounds having the general formula: in which R1, R2, R3, R4 and X are as defined by the present specification. In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.Type: GrantFiled: February 28, 2005Date of Patent: October 29, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hyun K. Kim, Richard P. Blye, Pemmaraju N. Rao, James W. Cessac, Carmie K. Acosta
-
Publication number: 20130274234Abstract: The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. New compounds and methods for treating these conditions are disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation.Type: ApplicationFiled: September 8, 2011Publication date: October 17, 2013Applicant: REPROS THERAPEUTICS INC.Inventors: Joseph S. Podolski, Ronald D. Wiehle
-
Patent number: 8536354Abstract: The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.Type: GrantFiled: March 16, 2009Date of Patent: September 17, 2013Assignee: Intrexon CorporationInventors: Robert E. Hormann, Silvia Lapenna, Laurence Neil Dinan
-
Publication number: 20130230588Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.Type: ApplicationFiled: April 15, 2013Publication date: September 5, 2013Applicant: TEMREL LIMITEDInventors: Christopher J. SPEIRS, Peter MOIR, Richard WILLIAMS, Michael CLARK
-
Publication number: 20130224123Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: December 4, 2012Publication date: August 29, 2013Applicant: Alkermes Pharma Ireland LimitedInventor: Alkermes Pharma Ireland Limited
-
Publication number: 20130225538Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: ETHICON, INC.Inventor: ETHICON, INC.
-
Patent number: 8518920Abstract: The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea.Type: GrantFiled: July 7, 2009Date of Patent: August 27, 2013Assignee: Nicox S.A.Inventors: Francesca Benedini, Annalisa Bonfanti, Valerio Chiroli, Rebecca Steele, Ennio Ongini, Stefano Biondi
-
Publication number: 20130213398Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: ApplicationFiled: August 26, 2011Publication date: August 22, 2013Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Patent number: 8513228Abstract: The present invention relates to novel crystalline Form A of 17?-acetoxy-21-methoxy-11?-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as CDB-4124) and methods for the preparation of it in excellent purity.Type: GrantFiled: March 22, 2010Date of Patent: August 20, 2013Assignee: Richter Gedeon Nyrt.Inventors: Csaba Santa, Adam Demeter, Balazs Havasi, Sandor Maho
-
Patent number: 8512745Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: a diluent in an amount of 60 to 95 wt %, a binding agent in an amount of 1 to 10 wt %, croscarmellose sodium in an amount of 1 to 10 wt %, and magnesium stearate in an amount of 0 to 5 wt %.Type: GrantFiled: December 8, 2008Date of Patent: August 20, 2013Assignee: Laboratoire HRA PharmaInventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Céline Gnakamene
-
Publication number: 20130209565Abstract: The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency.Type: ApplicationFiled: May 18, 2011Publication date: August 15, 2013Applicant: DuoCort Pharma ABInventors: Thomas Hedner, Ulrika Sigrid Helena Simonsson, Gudmundur Johannsson, Hans Lennernäs, Stanko Skrtic